Cargando…

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer

Patients with HPV-unrelated head and neck squamous cell carcinoma (HPV-unrelated HNSCC) show only modest benefit from treatment with PD-1 inhibitors (PD-1i). Targeting transforming growth factor β (TGF-β) may make PD-1i more effective by inducing T cell responses. In this issue of the JCI, Redman et...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bell, R. Bryan, Gough, Michael, Crittenden, Marka, Young, Kristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479756/ https://www.ncbi.nlm.nih.gov/pubmed/36106641 http://dx.doi.org/10.1172/JCI162733

Ejemplares similares

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)

Explant Modeling of the Immune Environment of Head and Neck Cancer
por: Sharon, Shay, et al.
Publicado: (2021)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

The Impact of the Myeloid Response to Radiation Therapy
por: Gough, Michael J., et al.
Publicado: (2013)

Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma
por: Uhde, Lauren, et al.
Publicado: (2015)

The TAM family as a therapeutic target in combination with radiation therapy
por: Tormoen, Garth W., et al.
Publicado: (2017)

Commentary: Moving beyond phenotypic diagnosis
por: Stansfield, William E.
Publicado: (2020)

Moving vaccination beyond partisan politics
por: Hoffman, Beth L., et al.
Publicado: (2022)

Programmed cell death-1 blockade in combination with stereotactic radiation in an orthotopic mouse model of hepatocellular carcinoma
por: Friedman, David, et al.
Publicado: (2015)

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
por: Santana‐Davila, Rafael, et al.
Publicado: (2017)

Tumor control by intravenous administration of STING ligand requires combination with precisely timed radiation therapy
por: Baird, Jason, et al.
Publicado: (2015)

The paradox of radiation and T cells in tumors
por: Gough, Michael J., et al.
Publicado: (2022)

Improved efficacy of radiation in combination with TGFβ inhibition in a colorectal cancer mouse model
por: Young, Kristina H, et al.
Publicado: (2013)

Assuring the quality of programmatic assessment: Moving beyond psychometrics
por: Uijtdehaage, Sebastian, et al.
Publicado: (2018)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
por: Sharon, Shay, et al.
Publicado: (2021)

Immunotherapy in head and neck squamous cell carcinoma: a narrative review
por: Sharon, Shay, et al.
Publicado: (2022)

National patient safety initiatives: Moving beyond what is necessary
por: Zimlichman, Eyal, et al.
Publicado: (2012)

Moving beyond the 'pancreatic rest' in severe and critical acute pancreatitis
por: Petrov, Maxim S
Publicado: (2013)

Moving Beyond Hip Fracture Risk Assessment for Patients on Dialysis
por: Nikkel, Lucas E.
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Moving beyond Definitive Therapy: Increasing Physical Activity in Survivors of Cancers of the Head and Neck
por: Nehlsen, Anthony D., et al.
Publicado: (2022)

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer
por: Runnels, Juliana, et al.
Publicado: (2023)

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
por: Young, Kristina H., et al.
Publicado: (2016)

Moving beyond tight glucose control to safe effective glucose control
por: Krinsley, James S, et al.
Publicado: (2008)

Diversity in optical coherence tomography normative databases: moving beyond race
por: Mehta, Nihaal, et al.
Publicado: (2020)

What’s missing in MHM? Moving beyond hygiene in menstrual hygiene management
por: Thomson, Jennifer, et al.
Publicado: (2019)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

Palliative Care and Patient Autonomy: Moving Beyond Prohibitions Against Hastening Death
por: LiPuma, Samuel H., et al.
Publicado: (2016)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer
por: Sharon, Shay, et al.
Publicado: (2023)

Moving beyond the individual: mHealth tools for social change in low-resource settings
por: McCool, Judith, et al.
Publicado: (2018)

From a distance to up close and contextual: Moving beyond the inductive/deductive binary
por: Brannen, Mary Yoko
Publicado: (2021)

Research and surgical residency: moving beyond one-and-done projects and motivating for scholarly excellence
por: Benesch, Matthew G.K., et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

FADD the bad in head and neck cancer
por: Dent, Paul
Publicado: (2013)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1uouaqh6gm8t7d7drl76equo28